FTC Chairwoman Lina Khan testifies during the House Appropriations Subcommittee on Financial Services and General Government hearing titled “Fiscal Year 2025 Request for the Federal Trade Commission,” in Rayburn Building on Wednesday, May 15, 2024. Tom Williams | Cq-roll Call, Inc. | Getty Images CVS Health, UnitedHealth Group and Cigna are demanding Federal Trade Commission…
Lina Khan, Chair of the Federal Trade Commission (FTC), testifies before the House Appropriations Subcommittee at the Rayburn House Office Building on May 15, 2024 in Washington, DC. Kevin Dietsch | Getty Images News | Getty Images The Federal Trade Commission on Friday sued three large U.S. health companies that negotiate insulin prices, arguing the…
Read More “FTC sues drug middlemen for allegedly inflating insulin prices” »
Eli Lilly’s highly popular weight loss drug reduced the risk of developing Type 2 diabetes by 94% in obese or overweight adults with prediabetes compared with a placebo, according to initial results from a long-term study released Tuesday. The late-stage trial on tirzepatide, the active ingredient in the company’s weight loss injection Zepbound and diabetes…
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023. Brendan McDermid | Reuters All doses of Eli Lilly’s highly popular weight loss injection Zepbound and diabetes drug Mounjaro are now available in the U.S., according to an update on the U.S. Food and Drug…
Read More “Eli Lilly’s Zepbound and Mounjaro now available in U.S. after shortages, FDA says” »
Kena Betancur | Corbis News | Getty Images Pfizer had a “phenomenal” first quarter — and Wall Street took notice, CEO Albert Bourla told thousands of employees during a companywide town hall on May 2, according to a recording heard by CNBC. A day earlier, the pharmaceutical giant’s stock had closed 6% higher after its…
Exterior view of the Pfizer headquarters building in New York City on Jan. 29, 2023. Kena Betancur | Corbis News | Getty Images Pfizer on Wednesday said it has launched a new multiyear program to reduce costs as it works to rebound from the rapid decline of its Covid business. The announcement is in addition…
Read More “Pfizer aims to save $1.5 billion by 2027 in first wave of new cost cuts” »
Amgen‘s stock rose more than 12% on Friday after the drugmaker teased positive initial data on its experimental weight loss injection. That fueled investor concerns about new competition in the rapidly growing weight loss drug industry, sending shares of the current obesity players, Novo Nordisk and Eli Lilly, lower on Friday. Eli Lilly shares dropped…
The Food and Drug Administration on Tuesday approved a drug from Merck designed to treat a progressive and life-threatening lung condition in a win for both the drugmaker and for patients suffering from the rare disease. The agency greenlighted the therapy, which will be marketed as Winrevair, for adults with pulmonary arterial hypertension. The decision…
Read More “FDA approves Merck’s drug for rare, deadly lung condition” »
A Humana Inc. office building in Louisville, Kentucky, Feb. 3, 2019. Bloomberg | Bloomberg | Getty Images Shares of Humana plummeted Thursday after the health insurer issued dismal full-year earnings guidance, citing soaring medical costs that are dogging the broader insurance industry. Those expenses have spiked as an increasing number of older adults return to…
Read More “Humana stock plunges on dismal 2024 forecast, as insurers face soaring medical costs” »
George Frey | Bloomberg | Getty Images Weight loss drugs exploded into the public eye this year, and 2024 will bring more change to the evolving market. The drugs skyrocketed in popularity in 2023 as they helped patients shed significant weight, despite hefty price tags, mixed insurance coverage and a handful of unpleasant side effects. …
Read More “The weight loss drug boom isn’t over yet — here’s what to expect in the year ahead” »
